Publications by authors named "Abdulaziz I Alnasser"
Article Synopsis
- A new LC-MS/MS method was created to simultaneously measure the drugs DCB and VTX in rat plasma, using encorafenib as an internal standard.
- The method included solid-phase extraction to prepare samples, achieving high recovery rates (90.68-97.56%) and validation according to FDA guidelines with low limits of detection (2.0 ng/mL).
- This innovative approach was applied in pharmacokinetic studies for rats given oral doses of 15.0 mg/kg of DCB and 100.0 mg/kg of VTX for the first time.
The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi, ENF) plus binimetinib (Mektovi, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Patients treated with combination therapy of ENF and BNB demonstrated a delay in resistance development, increases in antitumor activity, and attenuation of toxicities compared with the activity of either agent alone. However, the pharmacokinetic profile of the FDA-approved ENF and BNB is still unclear.
View Article and Find Full Text PDF